DXCM250103C100000
- 0.20
- 0.000.00%
DexCom Newsroom
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $86
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $115
RBC Capital Reaffirms Their Buy Rating on Dexcom (DXCM)
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
Wells Fargo Spotlights 31 Names It Believes 'Offer Above-average Growth Potential'
Wearable Patch Market Report 2025, With Profiles of Key Players Abbott, Medtronic, Dexcom, GlucoWatch, IRhythm Technologies, Insulet, Tactile Medical, VitalConnect, Qardio Myant & BioTelemetry
DexCom's (NASDAQ:DXCM) Returns On Capital Are Heading Higher
Chevron, PayPal Stock and These 8 US Names Are Best Ideas for Q1 2025 at BofA
The U.S. stock market officially closed for 2024! Among the components of the three major stock indices, who performed the best and who performed the worst?
AppLovin, a constituent stock of the Nasdaq, surged by 713%, becoming the biggest dark horse, with an increase more than four times that of AI leader NVIDIA.
These Are the Best and Worst Stocks This Year
DexCom Insiders Sold US$18m Of Shares Suggesting Hesitancy
Earnings Tell The Story For DexCom, Inc. (NASDAQ:DXCM)
At US$80.57, Is DexCom, Inc. (NASDAQ:DXCM) Worth Looking At Closely?
Abbott, DexCom Settlement 'Not a Complete Surprise,' Says Wells Fargo
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $94
Express News | Abbott Laboratories announced that it has reached an agreement with Medical Devices company DexCom to resolve all patent disputes between the two parties regarding continuous glucose monitoring devices.
Express News | DexCom and Abbott Laboratories have reached a settlement in the patent litigation.
DexCom, Abbott Agree to Settlement in Patent Litigation
Express News | Abbott: There Are No Financial Payments Associated With Settlement From Either Abbott or Dexcom
Express News | Abbott: Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom